We read with interest the study by Eriksen et al. regarding the impact of terlipressin on plasma sodium (PNa). 1 An analogue of vasopressin, terlipressin is used to treat the effects of systemic vasodilatation and renal dysfunction in patients with portal hypertension. It acts on vascular smooth muscle V 1 receptors to induce splanchnic vasoconstriction and on renal collecting duct V 2 receptors to mobilise aquaporin channels. 2 Eriksen et al. noted that these effects promote hyponatraemia and hypothesised that this may be more profound in non-cirrhotic patients, who do not demonstrate urinary sodium retention or high aquaporin expression at baseline. 2 The authors retrospectively compared PNa fluctuations in non-cirrhotics and cirrhotics with portal hypertension receiving bolus terlipressin for variceal bleeding.
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They found that non-cirrhotic patients had a greater reduction in mean PNa during terlipressin therapy (8.3 vs. 1.8 mmol/l, p ¼ 0.048) and a larger increase in mean PNa post its cessation (12.6 vs. 2.3 mmol/l, p ¼ 0.03). In both groups, an increased cumulative dose and duration of terlipressin was associated with more marked hyponatraemia (p ¼ 0.009 vs. p ¼ 0.02). They concluded that terlipressin posed a potentially dangerous risk of hyponatraemia in non-cirrhotic patients with variceal bleeding.
We agree that clinicians using terlipressin in this setting should proceed with caution, but offer safety data regarding its prolonged use in cirrhotic patients with other portal hypertensive complications. Based on safety and efficacy data from a Cochrane review and randomised control trial, 3, 4 our centre has developed a protocol for delivering continuous terlipressin infusion (CTI) in the outpatient setting to cirrhotics with hepatorenal syndrome (HRS) (as defined by the International Club of Ascites) 5 or refractory ascites who are awaiting liver transplantation. We have therefore prospectively observed the effect of CTI on PNa in this novel cohort.
Data was collected on all patients who received at least two weeks of CTI prior to 31 March 2018.
Patients commenced bolus terlipressin as inpatients (0.85 mg Q6h) and received volume expansion with albumin (40 g/day for three days). Suitable patients were transitioned to CTI. Informed consent was obtained and patients were transitioned to outpatient CTI, delivered via a peripherally inserted central (Figure 1 ). CTI was associated with a reduction in mean model for end stage liver disease with sodium (MELD-Na) score by 6 (27.1 to 21.1, p < 0.001). At final follow-up, 14 patients had undergone liver transplantation, three remained on CTI and two had ceased CTI (n ¼ 1 recovery post hepatitis C eradication, n ¼ 1 alcohol recidivism and delisting). There were no adverse events attributed directly to terlipressin therapy.
The difference in PNa profiles observed in the cirrhotic patients in Eriksen et al. and our cohorts is striking and warrants exploration. Potentially, mechanisms for this could relate to the disparate terlipressin dosing and indications. Bolus terlipressin results in higher daily doses and greater drug-level fluctuations compared with CTI, 4 which might contribute to greater PNa variation. In addition, patients with variceal bleeding are often hypovolaemic and receive intravenous crystalloids or blood products only when indicated; whereas patients with HRS and refractory ascites routinely receive albumin for volume expansion. In a recent narrative review by Papaluca et al., 7 the one study in which terlipressin increased PNa in cirrhotic patients was the only to use albumin routinely, 8 as also occurred in our study.
The potential influence of albumin administration on natremia is multifaceted. As a negatively charged molecule, albumin exerts a 'Gibbs-Donnan effect' to draw cations such as sodium into the vascular compartment. 9 Albumin is also a large protein, which increases oncotic pressure and therefore mobilises interstitial fluid into the intravascular space. This increases effective arterial blood volume, which subsequently downregulates baroreceptor activation, decreases endogenous vasopressin release and reduces water retention. Papaluca et al. postulated that this albumin-induced decrease in endogenous vasopressin might predominate over terlipressin-induced V 2 receptor activation, with the net result being free water clearance. 8 Ultimately, further research is needed to understand how terlipressin influences PNa, and the importance of factors beyond the patient's cirrhotic status. Baseline 
